Portal de Periódicos da CAPES

Artigo Acesso aberto Produção Nacional Revisado por pares

BIBTEX RIS

Myasthenia Gravis and COVID-19: Clinical Characteristics and Outcomes

2020; Frontiers Media; Volume: 11; Linguagem: Inglês

10.3389/fneur.2020.01053

1664-2295

Antônio Edvan Camelo-Filho, André Macedo Serafim Silva, Eduardo de Paula Estephan, Antônio A. Zambon, Rodrigo Holanda Mendonça, Paulo Victor Sgobbi de Souza, Wladimir Bocca Vieira de Rezende Pinto, Acary Souza Bullé Oliveira, Iron Dangoni-Filho, Ana Flávia Pincerno Pouza, Berenice Cataldo Oliveira Valério, Edmar Zanoteli,

COVID-19 Clinical Research Studies

Myasthenia gravis (MG), an autoimmune neuromuscular disorder, may be a risk factor for severe COVID-19. We conducted an observational retrospective study with 15 consecutive adult MG patients admitted with COVID-19 at four hospitals in São Paulo, Brazil. Most patients with MG hospitalized for COVID-19 had severe courses of the disease: 87% were admitted in the intensive care unit, 73% needed mechanical ventilation, and 30% died. Immunoglobulin use and the plasma exchange procedure were safe. Immunosuppressive therapy seems to be associated with better outcomes, as it might play a protective role.